PERCEPTIVE ADVISORS LLC
CIK: 0001224962Latest portfolio: $5.6B · Q4 2025
Holdings
116
Total Value
$5.6B
New Positions
39
Closed Positions
15
Top Holdings
View All 116 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | PRAXPRAXIS PRECISION MEDICINES I | 1,995,986 | $588.3M | 10.49% | +431K | |
| 2 | CELCCELCUITY INC | 3,160,200 | $315.2M | 5.62% | +204K | |
| 3 | RYTMRHYTHM PHARMACEUTICALS INC | 2,546,391 | $272.6M | 4.86% | -416,558,578 | |
| 4 | ASNDASCENDIS PHARMA A/S | 1,081,421 | $230.6M | 4.11% | -7,080 | |
| 5 | APGEAPOGEE THERAPEUTICS INC | 2,330,651 | $175.9M | 3.14% | +979K | |
| 6 | ROIVROIVANT SCIENCES LTD | 7,985,461 | $173.3M | 3.09% | +617K | |
| 7 | NUVLNUVALENT INC | 1,665,105 | $167.5M | 2.99% | +103K | |
| 8 | TVTXTRAVERE THERAPEUTICS INC | 4,278,180 | $163.5M | 2.91% | +484K | |
| 9 | XBISPDR SERIES TRUST | 1,100,000 | $134.1M | 2.39% | NEW | Put |
| 10 | EXASEXACT SCIENCES CORP | 1,200,487 | $121.9M | 2.17% | +735K | |
| 11 | PTGXPROTAGONIST THERAPEUTICS INC | 1,350,425 | $117.9M | 2.10% | +320K | |
| 12 | INBXINHIBRX BIOSCIENCES INC | 1,452,707 | $114.8M | 2.05% | +125K | |
| 13 | EWTXEDGEWISE THERAPEUTICS | 4,457,974 | $110.6M | 1.97% | +662K | |
| 14 | IMTXIMMATICS N.V | 10,383,456 | $109.0M | 1.94% | +1.0M | |
| 15 | SYRESPYRE THERAPEUTICS INC | 3,069,225 | $100.5M | 1.79% | +1.8M | |
| 16 | AMLXAMYLYX PHARMACEUTICALS INC | 8,284,882 | $100.1M | 1.78% | -667,483 | |
| 17 | ACLXARCELLX INC | 1,466,071 | $95.6M | 1.70% | -1,002,282 | |
| 18 | VRDNVIRIDIAN THERAPEUTICS INC | 3,042,703 | $94.7M | 1.69% | +1.6M | |
| 19 | BSXBOSTON SCIENTIFIC CORP | 979,000 | $93.3M | 1.66% | +669K | |
| 20 | AM6AMICUS THERAPEUTICS INC | 6,370,851 | $90.7M | 1.62% | — | |
| 21 | ZYMEZYMEWORKS INC | 3,261,850 | $85.9M | 1.53% | +1.2M | |
| 22 | CATBUSDASTRIA THERAPEUTICS INC | 6,485,420 | $84.9M | 1.51% | — | |
| 23 | MGTXMEIRAGTX HLDGS PLC | 10,326,103 | $82.1M | 1.46% | -2,300,000 | |
| 24 | AORTARTIVION INC | 1,722,290 | $78.6M | 1.40% | -297,710 | |
| 25 | CNTACENTESSA PHARMACEUTICALS PLC | 2,917,634 | $73.0M | 1.30% | -183,268 |
Quarterly Changes
New Positions
Increased Positions
Sector Breakdown
HealthcareNaN% ($InfinityT)
Unknown0.0% ($907208489436475162624.0T)
Financial Services0.0% ($134.1M)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $5.6B | 116 |
| Q3 2025 | Nov 14, 2025 | $3.5T | 93 |
| Q2 2025 | Aug 14, 2025 | $2.7T | 85 |
| Q1 2025 | May 15, 2025 | $2.8T | 87 |
| Q4 2024 | Feb 14, 2025 | $3.6T | 99 |
| Q3 2024 | Nov 14, 2024 | $4726.7T | 108 |
| Q2 2024 | Aug 14, 2024 | $4199.4T | 111 |
| Q1 2024 | May 15, 2024 | $5758.0T | 112 |
| Q4 2023 | Feb 14, 2024 | $4482.0T | 101 |
| Q3 2023 | Nov 14, 2023 | $2997.9T | 97 |
| Q2 2023 | Aug 14, 2023 | $3449.4T | 95 |
| Q1 2023 | May 15, 2023 | $3842.2T | 99 |
| Q4 2022 | Feb 14, 2023 | $3561.2T | 96 |
| Q3 2022 | Nov 14, 2022 | $3.4T | 116 |
| Q2 2022 | Aug 15, 2022 | $3.2T | 111 |
| Q1 2022 | May 16, 2022 | $5.0T | 135 |
| Q4 2021 | Feb 14, 2022 | $6.5T | 145 |
| Q3 2021 | Nov 15, 2021 | $6.9T | 140 |
| Q2 2021 | Aug 16, 2021 | $7.7T | 149 |
| Q1 2021 | May 17, 2021 | $7.9T | 138 |
| Q4 2020 | Feb 16, 2021 | $9.3T | 139 |
| Q3 2020 | Nov 16, 2020 | $6.8T | 126 |
| Q2 2020 | Aug 14, 2020 | $6.2T | 125 |
| Q1 2020 | May 15, 2020 | $3.8T | 113 |
| Q4 2019 | Feb 14, 2020 | $6.2T | 114 |
| Q3 2019 | Nov 14, 2019 | $3.7T | 109 |
| Q2 2019 | Aug 14, 2019 | $4.4T | 104 |
| Q1 2019 | May 15, 2019 | $3.5T | 105 |
| Q4 2018 | Feb 14, 2019 | $2.6T | 101 |
| Q3 2018 | Nov 14, 2018 | $3.7T | 117 |
| Q2 2018 | Aug 14, 2018 | $3.8T | 127 |
| Q1 2018 | May 15, 2018 | $3.6T | 137 |
| Q4 2017 | Feb 14, 2018 | $3.0T | 132 |
| Q3 2017 | Nov 14, 2017 | $2.6T | 139 |
| Q2 2017 | Aug 14, 2017 | $2.0T | 126 |
| Q1 2017 | May 15, 2017 | $1.8T | 173 |
| Q4 2016 | Feb 14, 2017 | $1.4T | 199 |
| Q3 2016 | Nov 14, 2016 | $1.5T | 196 |
| Q2 2016 | Aug 11, 2016 | $1.4T | 173 |
| Q1 2016 | May 16, 2016 | $1.1T | 170 |
Fund Information
PERCEPTIVE ADVISORS LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $5.6B across 116 holdings. The largest position is PRAXIS PRECISION MEDICINES I (PRAX), representing 10.5% of the portfolio. Compared to the previous quarter, the fund opened 39 new positions and closed 15 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.